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SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of health claims related to 
supercritical CO2 extracted blackcurrant seed oil and maintenance of 
normal blood pressure (ID 572) and maintenance of normal blood 
LDL-cholesterol concentrations (ID 572) pursuant to Article 13(1) of 
Regulation (EC) No 1924/2006
1
 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2, 3
 
European Food Safety Authority (EFSA), Parma, Italy 
SUMMARY 
Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and 
Allergies was asked to provide a scientific opinion on a list of health claims pursuant to Article 13 of 
Regulation (EC) No 1924/2006. This opinion addresses the scientific substantiation of health claims 
in relation to supercritical CO2 extracted blackcurrant seed oil and maintenance of normal blood 
pressure and maintenance of normal blood LDL-cholesterol concentrations. The scientific 
substantiation is based on the information provided by the Member States in the consolidated list of 
Article 13 health claims and references that EFSA has received from Member States or directly from 
stakeholders. 
The food that is the subject of the health claims is “blackcurrant seed oil (carbon dioxide 
extracted) + vitamin E”. From the information provided in the proposed health relationship and 
wordings, the Panel assumes that the food, which is the subject of the health claims, is supercritical 
carbon dioxide (CO2) extracted blackcurrant seed oil. The Panel considers that supercritical CO2 
extracted blackcurrant seed oil is sufficiently characterised. 
Maintenance of normal blood pressure 
The claimed effect is “cardiovascular system”. The target population is assumed to be the general 
population. In the context of the proposed wordings and clarifications provided by Member States, the 
Panel assumes that the claimed effect refers to the maintenance of normal blood pressure. The Panel 
considers that maintenance of normal blood pressure is a beneficial physiological effect. 
                                                     
1 On request from the European Commission, Question No EFSA-Q-2008-1359, adopted on 08 April 2011. 
2 Panel members: Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Hannu Korhonen, 
Pagona Lagiou, Martinus Løvik, Rosangela Marchelli, Ambroise Martin, Bevan Moseley, Monika Neuhäuser-Berthold, 
Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, Sean (J.J.) Strain, Stephan Strobel, Inge Tetens, Daniel Tomé, 
Hendrik van Loveren and Hans Verhagen. Correspondence: nda@efsa.europa.eu 
3  Acknowledgement: The Panel wishes to thank the members of the Working Group on Claims for the preparatory work on 
this scientific opinion: Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Marina 
Heinonen, Hannu Korhonen, Martinus Løvik, Ambroise Martin, Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, 
Sean (J.J.) Strain, Inge Tetens, Hendrik van Loveren and Hans Verhagen.  
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In weighing the evidence, the Panel took into account that the one human intervention study provided, 
from which conclusion can be drawn for the scientific substantiation of the claimed effect, did not 
show an effect of supercritical CO2 extracted blackcurrant seed oil on blood pressure. 
On the basis of the data presented, the Panel concludes that a cause and effect relationship has not 
been established between the consumption of supercritical CO2 extracted blackcurrant seed oil and 
maintenance of normal blood pressure. 
Maintenance of normal blood LDL-cholesterol concentrations 
The claimed effect is “cardiovascular system”. The target population is assumed to be the general 
population. In the context of the proposed wordings and clarifications provided by Member States, the 
Panel assumes that the claimed effect refers to the maintenance of normal blood LDL-cholesterol 
concentrations. The Panel considers that maintenance of normal blood LDL-cholesterol 
concentrations is a beneficial physiological effect. 
No studies, which investigated whether supercritical CO2 extracted blackcurrant seed oil has an 
LDL-cholesterol-lowering effect beyond what could be expected from its fatty acid composition, have 
been provided. 
On the basis of the data presented, the Panel concludes that a cause and effect relationship has not 
been established between the consumption of supercritical CO2 extracted blackcurrant seed oil and 
maintenance of normal blood LDL-cholesterol concentrations beyond what could be expected from its 
fatty acid composition. 
A claim on the replacement of mixtures of saturated fatty acids with cis-monounsaturated fatty acids 
and/or cis-polyunsaturated fatty acids in foods or diets and maintenance of normal blood LDL-
cholesterol concentrations, and claims on linoleic acid and on alpha-linolenic acid and maintenance of 
normal blood cholesterol concentrations have already been assessed with favourable outcomes.  
KEY WORDS 
Blackcurrant seed oil, LDL, blood cholesterol, blood pressure, health claims. 
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INFORMATION AS PROVIDED IN THE CONSOLIDATED LIST 
The consolidated list of health claims pursuant to Article 13 of Regulation (EC) No 1924/2006
4
 
submitted by Member States contains main entry claims with corresponding conditions of use and 
literature for similar health claims. EFSA has screened all health claims contained in the original 
consolidated list of Article 13 health claims which was received by EFSA in 2008 using six criteria 
established by the NDA Panel to identify claims for which EFSA considered sufficient information 
had been provided for evaluation and those for which more information or clarification was needed 
before evaluation could be carried out
5
. The clarifications which were received by EFSA through the 
screening process have been included in the consolidated list. This additional information will serve 
as clarification to the originally provided information. The information provided in the consolidated 
list for the health claims which are the subject of this opinion is tabulated in Appendix C. 
ASSESSMENT 
1. Characterisation of the food/constituent 
The food that is the subject of the health claims is “blackcurrant seed oil (carbon dioxide 
extracted) + vitamin E”. 
From the information provided in the proposed health relationship and wordings, the Panel assumes 
that the food that is the subject of the health claims is supercritical carbon dioxide (CO2) extracted 
blackcurrant seed oil (BSO).  
Supercritical CO2 is a fluid state of carbon dioxide where it is held at or above its critical temperature 
and critical pressure. The intention of such an extraction is that the relatively low temperature of the 
process and the stability of CO2 would allow most compounds to be extracted with little damage or 
denaturation. Supercritical CO2 extracted BSO contains approximately 47.5 % linoleic acid (LA) 
(18:2 n-6), 14.5 % α-linolenic acid (ALA) (18:3 n-3), 13.3 % oleic acid (18:1 n-9), 12.6 % γ-linolenic 
acid (GLA) (18:3 n-6), 5.6 % palmitic acid, 2.7 % stearidonic acid (18:4 n-3), and minor compounds 
of other fatty acids. It also contains 1.17 % free and esterified phytosterols, mainly sitosterol, 
1.28 mg/g α-tocopherol, 0.86 mg/g γ-tocopherol and 0.05 mg/g δ-tocopherol (Tahvonen et al., 2005). 
The Panel considers that the food, supercritical CO2 extracted blackcurrant seed oil, which is the 
subject of the health claims, is sufficiently characterised. 
2. Relevance of the claimed effect to human health 
2.1. Maintenance of normal blood pressure (ID 572) 
The claimed effect is “cardiovascular system”. The Panel assumes that the target population is the 
general population.  
In the context of the proposed wordings and clarifications provided by Member States, the Panel 
assumes that the claimed effect refers to the maintenance of normal blood pressure.  
                                                     
4 Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25.  
5 EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), 2011. General guidance for stakeholders on the 
evaluation of Article 13.1, 13.5 and 14 health claims. EFSA Journal, 9(4):2135, 24 pp. 
Supercritical CO2 extracted blackcurrant seed oil related health claims 
 
6 EFSA Journal 2011;9(6):2208 
Blood pressure is the pressure (force per unit area) exerted by circulating blood on the walls of blood 
vessels. Elevated blood pressure, by convention 140 mmHg (systolic) and/or 90 mmHg (diastolic), 
may compromise the normal function of the arteries. 
The Panel considers that maintenance of normal blood pressure is a beneficial physiological effect. 
2.2. Maintenance of normal blood LDL-cholesterol concentrations (ID 572) 
The claimed effect is “cardiovascular system”. The Panel assumes that the target population is the 
general population.  
In the context of the proposed wordings and clarifications provided by Member States, the Panel 
assumes that the claimed effect refers to the maintenance of normal blood LDL-cholesterol 
concentrations. 
Low-density lipoproteins (LDL) carry cholesterol from the liver to peripheral tissues, including the 
arteries. Elevated LDL-cholesterol, by convention >160 mg/dL (>4.1 mmol/L), may compromise the 
normal structure and function of the arteries. 
The Panel considers that maintenance of normal blood LDL-cholesterol concentrations is a beneficial 
physiological effect. 
3. Scientific substantiation of the claimed effect 
The references provided for the scientific substantiation of the claim included narrative reviews and 
monographs which referred to the clinical studies provided and described below. Some reviews and 
non-human studies were provided on the effects of unsaturated fatty acids, particularly of n-3 and n-6 
fatty acids. In three human studies, the effects of supercritical CO2 extracted blackcurrant seed oil 
were investigated.  
3.1. Maintenance of normal blood pressure (ID 572) 
One randomised controlled trial (RCT) evaluated the effect of 6 g supercritical CO2 extracted BSO 
consumed daily over eight weeks on resting blood pressure in 28 mildly hypertensive males (Deferne 
and Leeds, 1996). Subjects received three times per day four gelatine-coated capsules containing 
either 500 mg BSO (n=14) or capsules with 500 mg safflower oil (control, n=14). One subject 
dropped out in the control group after five weeks of treatment for reasons unrelated to the study. 
Resting blood pressure was measured, after an overnight fast, at baseline and weekly for the duration 
of the study. No significant differences in systolic or diastolic blood pressure were observed between 
BSO and control groups at any time point during the study. The Panel notes that this study does not 
show an effect of BSO on blood pressure.  
In weighing the evidence, the Panel took into account that the one human intervention study provided, 
from which conclusion can be drawn for the scientific substantiation of the claimed effect, did not 
show an effect of supercritical CO2 extracted BSO on blood pressure. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of supercritical CO2 extracted blackcurrant seed oil and maintenance of normal blood 
pressure. 
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3.2. Maintenance of normal blood LDL-cholesterol concentrations (ID 572) 
A double-blind RCT with a cross-over design compared the effects of 3 g/day supercritical CO2 
extracted BSO with 2.8 g/day fish oil on blood lipids in 15 healthy females (Tahvonen et al., 2005). 
The two treatment periods and the wash-out phase lasted four weeks each. The fish oil contained 
about 30 % saturated fatty acids (SFAs), 24 % long-chain polyunsaturated fatty acids (LC-PUFAs), 
28 % monounsaturated fatty acids (MUFAs), 6 % polyunsaturated fatty acids (PUFAs) and minor 
amounts of other fatty acids. A 4.9 % reduction in LDL-cholesterol concentrations during the BSO 
period and a 3.6 % increase in LDL-cholesterol concentrations during the fish oil period were 
observed. The between-group difference was statistically significant (p<0.05). The Panel notes that 
the difference in LDL-cholesterol concentrations observed between the BSO and the fish oil 
interventions could be explained by the different fatty acid composition of the oils (e.g. replacement 
of SFAs and LC-PUFAs in the fish oil by PUFAs in the BSO oil).  
An unpublished manuscript reported on a double-blind, cross-over RCT which compared the effects 
of 5 g/day supercritical CO2 extracted BSO and of 5 g/day olive oil (about 70 % oleic acid, 
15 % SFAs, and 11 % PUFAs, mainly LA) on blood lipids in 12 normolipidaemic males (Johansson, 
1999). The treatment periods lasted four weeks each with a wash-out phase of 4-8 weeks in between. 
The Panel notes the presence of carry-over effects between intervention periods and considers that no 
conclusions can be drawn from this study for the scientific substantiation of the claim.  
No studies, which investigated whether supercritical CO2 extracted BSO has an LDL-cholesterol-
lowering effect beyond what could be expected from its fatty acid composition, have been provided. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of supercritical CO2 extracted BSO and maintenance of normal blood LDL-cholesterol 
concentrations beyond what could be expected from its fatty acid composition.  
A claim on the replacement of mixtures of SFAs with cis-MUFAs and/or cis-PUFAs in foods or diets 
and maintenance of normal blood LDL-cholesterol concentrations has already been assessed with a 
favourable outcome (EFSA Panel on Dietetic Products Nutrition and Allergies (NDA), 2011). 
A claim on linoleic acid and maintenance of normal blood cholesterol concentrations has also already 
been assessed with a favourable outcome (EFSA Panel on Dietetic Products Nutrition and Allergies 
(NDA), 2009a).  
A claim on alpha-linolenic acid and maintenance of normal blood cholesterol concentrations has also 
already been assessed with a favourable outcome (EFSA Panel on Dietetic Products Nutrition and 
Allergies (NDA), 2009b).  
CONCLUSIONS  
On the basis of the data presented, the Panel concludes that: 
 The food, supercritical CO2 extracted blackcurrant seed oil, which is the subject of the health 
claims, is sufficiently characterised. 
Maintenance of normal blood pressure (ID 572) 
 The claimed effect is “cardiovascular system”. The target population is assumed to be the 
general population. In the context of the proposed wordings and clarifications provided by 
Member States, it is assumed that the claimed effect refers to the maintenance of normal 
blood pressure. Maintenance of normal blood pressure is a beneficial physiological effect. 
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 A cause and effect relationship has not been established between the consumption of 
supercritical CO2 extracted blackcurrant seed oil and maintenance of normal blood pressure. 
Maintenance of normal blood LDL-cholesterol concentrations (ID 572) 
 The claimed effect is “cardiovascular system”. The target population is assumed to be the 
general population. In the context of the proposed wordings and clarifications provided by 
Member States, it is assumed that the claimed effect refers to maintenance of normal blood 
LDL-cholesterol concentrations. Maintenance of normal blood LDL-cholesterol 
concentrations is a beneficial physiological effect. 
 A cause and effect relationship has not been established between the consumption of 
supercritical CO2 extracted blackcurrant seed oil and maintenance of normal blood LDL-
cholesterol concentrations beyond what could be expected from its fatty acid composition. 
 A claim on the replacement of mixtures of SFAs with cis-MUFAs and/or cis-PUFAs in foods 
or diets and maintenance of normal blood LDL-cholesterol concentrations, and claims on 
linoleic acid and on alpha-linolenic acid and maintenance of normal blood cholesterol 
concentrations have already been assessed with favourable outcomes. 
DOCUMENTATION PROVIDED TO EFSA 
Health claims pursuant to Article 13 of Regulation (EC) No 1924/2006 (No: EFSA-Q-2008-1359). 
The scientific substantiation is based on the information provided by the Member States in the 
consolidated list of Article 13 health claims and references that EFSA has received from Member 
States or directly from stakeholders. 
The full list of supporting references as provided to EFSA is available on: 
http://www.efsa.europa.eu/panels/nda/claims/article13.htm. 
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APPENDICES 
APPENDIX A 
BACKGROUND AND TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
The Regulation 1924/2006 on nutrition and health claims made on foods
6
 (hereinafter "the 
Regulation") entered into force on 19
th
 January 2007. 
Article 13 of the Regulation foresees that the Commission shall adopt a Community list of permitted 
health claims other than those referring to the reduction of disease risk and to children's development 
and health. This Community list shall be adopted through the Regulatory Committee procedure and 
following consultation of the European Food Safety Authority (EFSA). 
Health claims are defined as "any claim that states, suggests or implies that a relationship exists 
between a food category, a food or one of its constituents and health".  
In accordance with Article 13 (1) health claims other than those referring to the reduction of disease 
risk and to children's development and health are health claims describing or referring to:  
a) the role of a nutrient or other substance in growth, development and the functions of the 
body; or 
b) psychological and behavioural functions; or 
c) without prejudice to Directive 96/8/EC, slimming or weight-control or a reduction in the 
sense of hunger or an increase in the sense of satiety or to the reduction of the available 
energy from the diet. 
To be included in the Community list of permitted health claims, the claims shall be:  
(i) based on generally accepted scientific evidence; and 
(ii) well understood by the average consumer. 
Member States provided the Commission with lists of claims as referred to in Article 13 (1) by 31 
January 2008 accompanied by the conditions applying to them and by references to the relevant 
scientific justification. These lists have been consolidated into the list which forms the basis for the 
EFSA consultation in accordance with Article 13 (3).  
ISSUES THAT NEED TO BE CONSIDERED 
IMPORTANCE AND PERTINENCE OF THE FOOD
7
  
Foods are commonly involved in many different functions
8
 of the body, and for one single food many 
health claims may therefore be scientifically true. Therefore, the relative importance of food e.g. 
nutrients in relation to other nutrients for the expressed beneficial effect should be considered: for 
functions affected by a large number of dietary factors it should be considered whether a reference to 
a single food is scientifically pertinent.  
                                                     
6 OJ L12, 18/01/2007 
7 The term 'food' when used in this Terms of Reference refers to a food constituent, the food or the food category.  
8 The term 'function' when used in this Terms of Reference refers to health claims in Article 13(1)(a), (b) and (c).   
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It should also be considered if the information on the characteristics of the food contains aspects 
pertinent to the beneficial effect.  
SUBSTANTIATION OF CLAIMS BY GENERALLY ACCEPTABLE SCIENTIFIC EVIDENCE 
Scientific substantiation is the main aspect to be taken into account to authorise health claims. Claims 
should be scientifically substantiated by taking into account the totality of the available scientific 
data, and by weighing the evidence, and shall demonstrate the extent to which: 
(a) the claimed effect of the food is beneficial for human health, 
(b) a cause and effect relationship is established between consumption of the food and the 
claimed effect in humans (such as: the strength, consistency, specificity, dose-
response, and biological plausibility of the relationship), 
(c) the quantity of the food and pattern of consumption required to obtain the claimed 
effect could reasonably be achieved as part of a balanced diet, 
(d) the specific study group(s) in which the evidence was obtained is representative of the 
target population for which the claim is intended. 
EFSA has mentioned in its scientific and technical guidance for the preparation and presentation of 
the application for authorisation of health claims consistent criteria for the potential sources of 
scientific data. Such sources may not be available for all health claims. Nevertheless it will be 
relevant and important that EFSA comments on the availability and quality of such data in order to 
allow the regulator to judge and make a risk management decision about the acceptability of health 
claims included in the submitted list. 
The scientific evidence about the role of a food on a nutritional or physiological function is not 
enough to justify the claim. The beneficial effect of the dietary intake has also to be demonstrated. 
Moreover, the beneficial effect should be significant i.e. satisfactorily demonstrate to beneficially 
affect identified functions in the body in a way which is relevant to health. Although an appreciation 
of the beneficial effect in relation to the nutritional status of the European population may be of 
interest, the presence or absence of the actual need for a nutrient or other substance with nutritional or 
physiological effect for that population should not, however, condition such considerations. 
Different types of effects can be claimed. Claims referring to the maintenance of a function may be 
distinct from claims referring to the improvement of a function. EFSA may wish to comment whether 
such different claims comply with the criteria laid down in the Regulation. 
WORDING OF HEALTH CLAIMS 
Scientific substantiation of health claims is the main aspect on which EFSA's opinion is requested. 
However, the wording of health claims should also be commented by EFSA in its opinion. 
There is potentially a plethora of expressions that may be used to convey the relationship between the 
food and the function. This may be due to commercial practices, consumer perception and linguistic 
or cultural differences across the EU. Nevertheless, the wording used to make health claims should be 
truthful, clear, reliable and useful to the consumer in choosing a healthy diet. 
In addition to fulfilling the general principles and conditions of the Regulation laid down in Article 3 
and 5, Article 13(1)(a) stipulates that health claims shall describe or refer to "the role of a nutrient or 
other substance in growth, development and the functions of the body". Therefore, the requirement to 
describe or refer to the 'role' of a nutrient or substance in growth, development and the functions of 
the body should be carefully considered. 
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The specificity of the wording is very important. Health claims such as "Substance X supports the 
function of the joints" may not sufficiently do so, whereas a claim such as "Substance X helps 
maintain the flexibility of the joints" would. In the first example of a claim it is unclear which of the 
various functions of the joints is described or referred to contrary to the latter example which 
specifies this by using the word "flexibility". 
The clarity of the wording is very important. The guiding principle should be that the description or 
reference to the role of the nutrient or other substance shall be clear and unambiguous and therefore 
be specified to the extent possible i.e. descriptive words/ terms which can have multiple meanings 
should be avoided. To this end, wordings like "strengthens your natural defences" or "contain 
antioxidants" should be considered as well as "may" or "might" as opposed to words like 
"contributes", "aids" or "helps".  
In addition, for functions affected by a large number of dietary factors it should be considered 
whether wordings such as "indispensable", "necessary", "essential" and "important" reflects the 
strength of the scientific evidence. 
Similar alternative wordings as mentioned above are used for claims relating to different relationships 
between the various foods and health. It is not the intention of the regulator to adopt a detailed and 
rigid list of claims where all possible wordings for the different claims are approved. Therefore, it is 
not required that EFSA comments on each individual wording for each claim unless the wording is 
strictly pertinent to a specific claim. It would be appreciated though that EFSA may consider and 
comment generally on such elements relating to wording to ensure the compliance with the criteria 
laid down in the Regulation. 
In doing so the explanation provided for in recital 16 of the Regulation on the notion of the average 
consumer should be recalled. In addition, such assessment should take into account the particular 
perspective and/or knowledge in the target group of the claim, if such is indicated or implied. 
TERMS OF REFERENCE 
HEALTH CLAIMS OTHER THAN THOSE REFERRING TO THE REDUCTION OF DISEASE RISK AND TO 
CHILDREN'S DEVELOPMENT AND HEALTH 
EFSA should in particular consider, and provide advice on the following aspects:  
 Whether adequate information is provided on the characteristics of the food pertinent to the 
beneficial effect. 
 Whether the beneficial effect of the food on the function is substantiated by generally 
accepted scientific evidence by taking into account the totality of the available scientific data, 
and by weighing the evidence. In this context EFSA is invited to comment on the nature and 
quality of the totality of the evidence provided according to consistent criteria. 
 The specific importance of the food for the claimed effect. For functions affected by a large 
number of dietary factors whether a reference to a single food is scientifically pertinent.  
In addition, EFSA should consider the claimed effect on the function, and provide advice on the 
extent to which: 
 the claimed effect of the food in the identified function is beneficial. 
 a cause and effect relationship has been established between consumption of the food and the 
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claimed effect in humans and whether the magnitude of the effect is related to the quantity 
consumed. 
 where appropriate, the effect on the function is significant in relation to the quantity of the 
food proposed to be consumed and if this quantity could reasonably be consumed as part of a 
balanced diet.  
 the specific study group(s) in which the evidence was obtained is representative of the target 
population for which the claim is intended. 
 the wordings used to express the claimed effect reflect the scientific evidence and complies 
with the criteria laid down in the Regulation.  
When considering these elements EFSA should also provide advice, when appropriate: 
 on the appropriate application of Article 10 (2) (c) and (d) in the Regulation, which provides 
for additional labelling requirements addressed to persons who should avoid using the food; 
and/or warnings for products that are likely to present a health risk if consumed to excess. 
Supercritical CO2 extracted blackcurrant seed oil related health claims 
 
14 EFSA Journal 2011;9(6):2208 
APPENDIX B 
EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation to the marketing 
of the food/food constituent, a positive assessment of its safety, nor a decision on whether the 
food/food constituent is, or is not, classified as foodstuffs. It should be noted that such an assessment 
is not foreseen in the framework of Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wordings of the claims and the conditions of 
use as proposed in the Consolidated List may be subject to changes, pending the outcome of the 
authorisation procedure foreseen in Article 13(3) of Regulation (EC) No 1924/2006. 
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APPENDIX C 
Table 1. Main entry health claims related to supercritical CO2 extracted blackcurrant seed oil, 
including conditions of use from similar claims, as proposed in the Consolidated List. 
ID Food or Food constituent Health Relationship Proposed wording 
572 Blackcurrant seed oil 
(carbon dioxide extracted) + 
vitamin E. 
 
Cardiovascular system. 
Clarification provided 
Blackcurrant seed oil 
helps to maintain 
healthy cholesterol 
levels. 
Blackcurrant seed oil 
helps to maintain 
normal blood pressure. 
Blackcurrant seed oil increases HDL 
cholesterol levels. 
Blackcurrant seed oil reduces LDL 
cholesterol levels. 
Blackcurrant seed oil improves the 
HDL/LDL ratio. 
Blackcurrant seed oil supports 
cardiovascular health by regulating 
fat metabolism and blood pressure. 
Conditions of use 
- Food supplement with 100-2000 mg of blackcurrant seed oil (standardised, carbon dioxide 
extracted) and 5-10 mg of vitamin E in the daily dose. 
Comments from Member States 
Health relationship defined. 
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GLOSSARY AND ABBREVIATIONS 
ALA  α-linolenic acid 
BSO  Blackcurrant seed oil 
GLA  γ-linolenic acid 
HDL  High density lipoprotein 
LA  Linoleic acid 
LC-PUFA Long-chain polyunsaturated fatty acid 
LDL  Low density lipoprotein 
MUFA  Monounsaturated fatty acid 
PUFA  Polyunsaturated fatty acid 
RCT  Randomised controlled trial 
SFA  Saturated fatty acid 
